Eli Lilly and stock is trading -14.05% below its average target price of $889.69 after marking a 2.2% during today's afternoon session. Analysts are giving the Large-Cap Pharmaceutical company an average rating of buy and target prices ranging from $650.0 to $1190.0 per share.
The stock has a very low short interest at 1.0%, and a short ratio of 1.22. The company's insiders own 0.16% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 83.9% of Eli Lilly and's shares being owned by this investor type.
Institutions Invested in Eli Lilly and
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2025-06-30 | Lilly Endowment, Inc | 10% | 96,016,978 | $73,420,339,818 |
| 2025-06-30 | Vanguard Group Inc | 8% | 80,407,430 | $61,484,343,264 |
| 2025-06-30 | Blackrock Inc. | 7% | 65,961,661 | $50,438,241,928 |
| 2025-06-30 | PNC Financial Services Group, Inc. | 5% | 51,293,980 | $39,222,453,369 |
| 2025-06-30 | State Street Corporation | 4% | 34,506,968 | $26,386,097,224 |
| 2025-06-30 | FMR, LLC | 3% | 25,629,773 | $19,598,061,533 |
| 2025-06-30 | Capital Research Global Investors | 2% | 20,756,363 | $15,871,559,974 |
| 2025-06-30 | Geode Capital Management, LLC | 2% | 18,128,627 | $13,862,235,434 |
| 2025-06-30 | Capital World Investors | 2% | 17,634,492 | $13,484,390,179 |
| 2025-06-30 | Price (T.Rowe) Associates Inc | 2% | 16,845,105 | $12,880,777,536 |
Besides an analyst consensus of some upside potential, other market factors point to there being mixed market sentiment on Eli Lilly and.
